or greater than 68.7% was associated with pCR in 57.4% of patients (31 of 54) compared with 16.7% of patients (9 of 54) with a decrease less than 68.7% (OR, 6.74; 95% CI, 2.75-16.51; \( P < .001 \)).

This article has been corrected online.


**Error in Abstract:** In the Original Investigation titled “Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer,” published online July 8, 2021, there was an error in the Results section of the Abstract. The median (interquartile range) overall survival and time on treatment was 43 (16.2-unavailable) and 14 (6.0-26.2) months, respectively, among the cohort of patients who received pertuzumab, rather than the entire population. This article has been corrected online.